Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NRIXVery BullishCorporate Developmentsnews

High materiality9/10

Nurix inks Roche collaboration for NX-5948 with up to $2.3B

Jul 9, 2026, 4:05 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Significant upfront cash improves liquidity and reduces near-term burn; milestone upside could drive equity re-rating; data at EHA adds clinical validation; historically, Roche collaborations yield immediate stock moves for biotechs.

AI summary

What happened, with direct paths to the underlying reporting

Nurix and Roche signed a global NX-5948 collaboration with a $700M upfront and up to $2.3B in milestones. Nurix bears 40/60 development costs and a 50/50 US profit split, with royalties ex-US. The deal funds DAYBreak CLL trials and CSU/MS expansion, supported by compelling EHA data.

Nurix and Roche announce global NX-5948 collaboration. Upfront $700M; milestones up to $2.3B.
Co-development and co-commercialization; 40/60 cost split. US profits 50/50; ex-US royalties.
Expansion into CSU and MS with planned Phase 2s. Broad hematology, immunology, neurology scope.
EHA data show durable responses; ORR 83%. PFS 22.1 months.
Closing conditions: Hart-Scott-Rodino and antitrust clearances. Timing Q3 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Nurix inks Roche collaboration for NX-5948 with up to $2.3B

Roche-Nurix alliance on NX-5948 boosts NRIX with upfront cash and milestones

How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%